查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621344

性行为感染传染病诊断市场：按疾病类型、诊断方法、设备类型和最终用户划分 - 2025-2030 年全球预测

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，性行为感染传染病诊断市场价值为1,065.3亿美元，预计到2024年将达到1,125.6亿美元，复合年增长率为5.97%，到2030年将达到1,599.7亿美元。

性行为感染传染病（STD）诊断市场范围包括用于识别透过性接触传播的感染疾病的各种测试和技术，例如爱滋病毒、梅毒、淋病和披衣菌感染。诊断试剂对于公共卫生至关重要，能够及早发现和治疗以防止感染传播。这些诊断的应用范围从医疗保健设施到家庭检测套组，为医院、诊所和个人消费者提供解决方案。最终使用领域包括公共卫生实验室、私人诊所和研究组织。市场成长受到人们对性健康的认识不断提高、政府对性病认识和控制的倡议不断加强以及快速就地检验和核酸增幅检查等检测方法的技术进步的显着影响。这些进步提供了更快、更准确的结果，提高了用户便利性并推动了市场需求。潜在的商机存在于新兴市场，这些市场的意识计画正在改善，诊断技术的采用也正在增加。诊断公司和医疗保健提供者之间的策略伙伴关係可以扩大影响力和影响力。然而，他们面临着诸如与性传染病相关的社会耻辱、先进诊断测试的高昂成本以及限制公共卫生干预措施的监管障碍等挑战。也存在一些限制，例如影响可及性的地区之间医疗基础设施的差异。完美的创新领域包括开发具有成本效益且易于使用的家庭测试解决方案、整合人工智慧以个人化治疗计划以及提高测试灵敏度和特异性。可以同时识别多种感染疾病的多重诊断的研究是有希望的。 STD 诊断市场是一个由技术创新驱动但受到社会障碍阻碍的动态市场，公司专注于医疗保健服务的文化能力并发展合作关係以有效克服这些挑战。

主要市场统计
基准年[2023] 1065.3亿美元
预计年份 [2024] 1125.6亿美元
预测年份 [2030] 1599.7亿美元
复合年增长率（%） 5.97%

市场动态：针对快速发展的性行为感染诊断市场所揭示的关键市场见解

供需的动态交互作用正在改变性行为感染传染病诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球性病患病率上升以及对有效诊断解决方案的需求
    • 加强全球筛检实践，以减少性传染病的耻辱
  • 市场限制因素
    • 对性病缺乏足够的认知与教育
  • 市场机会
    • 增加资金和公共卫生宣传活动以提高性病意识和预防
    • 次世代定序仪和基于 CRISPR 的诊断的创新
  • 市场挑战
    • 政府对药物核准和未经治疗的感染疾病引起的併发症有严格的规定

波特五力：驾驭性行为感染诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对性行为感染传染病诊断市场的影响

外部宏观环境因素在塑造性行为感染传染病诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解性行为感染传染病诊断市场的竞争状况

对性行为感染诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵性行为感染诊断市场供应商绩效评估

FPNV定位矩阵是评估性行为感染传染病诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘性行为感染诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对性行为感染诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地性传染病的日益普及增加了对有效诊断解决方案的需求。
      • 在全球范围内增加检测，以减少与性行为感染感染相关的耻辱
    • 抑制因素
      • 对性行为感染传染病缺乏足够的认知与教育
    • 机会
      • 增加对性行为感染传染病的认识和预防的资金和公共卫生宣传活动
      • 次世代定序和基于 CRISPR 的诊断的创新
    • 任务
      • 政府对药物核准和未经治疗的感染疾病引起的併发症有严格的规定
  • 市场区隔分析
    • 疾病类型：次世代定序和基于 CRISPR 的诊断技术的进步可解决多种 STD
    • 最终用户：在临床和医院环境中更多地采用性病诊断来解决复杂的性病病例
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章性行为感染传染病诊断市场：依疾病类型

  • 细菌性阴道炎
  • 念珠菌性阴道炎
  • 披衣菌感染披衣菌/淋病双球菌
  • 尖圭湿疣
  • B型肝炎
  • 爱滋病毒/爱滋病
  • 生殖霉浆菌
  • 梅毒
  • 滴虫病

第七章依诊断方法性行为感染传染病诊断药物市场

  • 抗原检测
  • 分子诊断
  • 血清学检测

第八章按设备类型分類的性行为感染传染病诊断市场

  • 实验设备
    • 吸光度微孔盘
    • 动态光散射装置
    • 流式细胞仪
    • 侧向流读取仪
    • 聚合酵素连锁反应热迴圈仪-PCR
  • 照护现场设备
    • 电话晶片（微流体+ICT）
    • 快速诊断试剂套件

第九章性行为感染诊断市场：依最终用户分类

  • 诊所
  • 诊断实验室
  • 医院
  • 公共卫生机构
  • 调查机构

第十章 南北美洲性行为感染诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太性行为感染诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲性行为感染诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • 英国Start-Ups推出性行为感染感染测试功能的卫生棉条
    • BioPerfectus 推出新型 PCR 试剂套件，用于性行为感染传染病诊断解决方案
    • MyLab 推出性行为感染传染病快速检测
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Astra Biotech Gmbh
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Qiagen Inc
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-6D54EA0F9447

The Sexually Transmitted Disease Diagnostics Market was valued at USD 106.53 billion in 2023, expected to reach USD 112.56 billion in 2024, and is projected to grow at a CAGR of 5.97%, to USD 159.97 billion by 2030.

The scope of the Sexually Transmitted Disease (STD) Diagnostics market encompasses the various tests and technologies used to identify infections transmitted through sexual contact, including HIV, syphilis, gonorrhea, chlamydia, and more. Diagnostics are essential for public health, enabling early detection and treatment to prevent the spread of infections. Applications of these diagnostics range from healthcare facilities to home-based testing kits, offering solutions for hospitals, clinics, and individual consumers. End-use segments include public health laboratories, private clinics, and research institutes. Market growth is significantly influenced by rising awareness of sexual health, increased government initiatives for STD awareness and control, and technological advancements in testing methods, such as rapid point-of-care tests and nucleic acid amplification tests. These advancements offer faster and more accurate results, thereby enhancing user convenience and boosting market demand. Potential opportunities lie in emerging markets where awareness programs are improving and the adoption of diagnostics is increasing. Strategic partnerships between diagnostic companies and healthcare providers can enhance reach and impact. However, market growth faces challenges such as social stigma associated with STDs, the high cost of advanced diagnostic tests, and regulatory hurdles that can limit public health intervention efforts. Limitations also include disparity in healthcare infrastructure across regions, affecting accessibility. The best areas for innovation include developing cost-effective and user-friendly home testing solutions, integrating artificial intelligence to personalize treatment plans, and improving sensitivity and specificity of tests. Research into multiplex diagnostics that can identify multiple infections simultaneously is promising. The STD Diagnostics market is dynamic, driven by technological innovation yet hindered by societal barriers, suggesting businesses focus on cultural competence in healthcare delivery and form collaborative relationships to navigate these challenges effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 106.53 billion
Estimated Year [2024] USD 112.56 billion
Forecast Year [2030] USD 159.97 billion
CAGR (%) 5.97%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sexually Transmitted Disease Diagnostics Market

The Sexually Transmitted Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
    • Increasing implementation of worldwide screening to reduce the stigma associated with STD
  • Market Restraints
    • Lack of adequate awareness and education about STDs
  • Market Opportunities
    • Increased funding and public health campaigns for STD awareness and prevention
    • Innovations in next-generation sequencing and CRISPR-based diagnostics
  • Market Challenges
    • Stringent government regulations for drug approvals and complications arising from untreated infections

Porter's Five Forces: A Strategic Tool for Navigating the Sexually Transmitted Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sexually Transmitted Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sexually Transmitted Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sexually Transmitted Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sexually Transmitted Disease Diagnostics Market

A detailed market share analysis in the Sexually Transmitted Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sexually Transmitted Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sexually Transmitted Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sexually Transmitted Disease Diagnostics Market

A strategic analysis of the Sexually Transmitted Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Bacterial Vaginosis, Candidal Vaginitis, Chlamydia Trachomatis/ Neisseria Gonorrhoeae, Genital Warts, Hepatitis B, HIV/AIDS, Mycoplasma Genitalium, Syphilis, and Trichomoniasis.
  • Based on Diagnostic methods, market is studied across Antigen Detection, Molecular Diagnostics, and Serologic Testing.
  • Based on Device Type, market is studied across Laboratory Devices and Point of Care Devices. The Laboratory Devices is further studied across Absorbance Microplate Reader, Differential Light Scattering Machines, Flow Cytometers, Lateral Flow Readers, and Thermal Cyclers - PCR. The Point of Care Devices is further studied across Phone Chips (Microfluidics + ICT) and Rapid Diagnostic Kits.
  • Based on End-Users, market is studied across Clinics, Diagnostic Laboratories, Hospitals, Public Health Agencies, and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
      • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of adequate awareness and education about STDs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
      • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
    • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Bacterial Vaginosis
  • 6.3. Candidal Vaginitis
  • 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
  • 6.5. Genital Warts
  • 6.6. Hepatitis B
  • 6.7. HIV/AIDS
  • 6.8. Mycoplasma Genitalium
  • 6.9. Syphilis
  • 6.10. Trichomoniasis

7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

  • 7.1. Introduction
  • 7.2. Antigen Detection
  • 7.3. Molecular Diagnostics
  • 7.4. Serologic Testing

8. Sexually Transmitted Disease Diagnostics Market, by Device Type

  • 8.1. Introduction
  • 8.2. Laboratory Devices
    • 8.2.1. Absorbance Microplate Reader
    • 8.2.2. Differential Light Scattering Machines
    • 8.2.3. Flow Cytometers
    • 8.2.4. Lateral Flow Readers
    • 8.2.5. Thermal Cyclers - PCR
  • 8.3. Point of Care Devices
    • 8.3.1. Phone Chips (Microfluidics + ICT)
    • 8.3.2. Rapid Diagnostic Kits

9. Sexually Transmitted Disease Diagnostics Market, by End-Users

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals
  • 9.5. Public Health Agencies
  • 9.6. Research Institutions

10. Americas Sexually Transmitted Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. British startup launches tampon that offers STI screening
    • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
    • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astra Biotech Gmbh
  • 3. Becton Dickinson and company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. Daye Limited
  • 8. Diasorin S.p.A
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Geneproof
  • 11. Hologic Inc.
  • 12. Jiangsu BioPerfectus Technologies Co., Ltd
  • 13. Liferiver Bio-Tech Corp.
  • 14. MedMira Inc
  • 15. Meridian Bioscience Inc.
  • 16. Mylab Discovery Solutions Pvt. Ltd.
  • 17. OraSure Technologies, Inc.
  • 18. Qiagen Inc
  • 19. Quest Consumer Inc.
  • 20. Sansure Biotech Inc.
  • 21. Seegene Inc.
  • 22. Siemens Healthcare GmbH
  • 23. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)

T